Published DateClear

Start Date

End Date

Category

• Business1
• Pipeline1

Organizations

• Bausch + Lomb73
• Eyes On Eyecare56
• Alcon, Inc.50
• American Optometric Association42
• Harrow34
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Coopervision22
• Aldeyra Therapeutics21

Tags

• AMD2
• DME2
• Wet Amd2
• Business Management1
• Clinical Trials1
• Finance1
• Finances1
• Retina1

• Organizations: Ollin Biosciences✕

Clear all

Pipeline

Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD

Financing to support global clinical development of its bispecific antibody programs following promising phase 1b data readout in a head-to-head against faricimab.

Business

Ollin Biosciences debuts with next-gen ophthalmic pipeline

Biotech launches with $100 million financing and a lead program addressing wet AMD and DME via a higher potency VEGF/Ang2 bispecific antibody.